Health Economics›Breast cancer›Metastatic disease subsequent lines of chemotherapy

Metastatic disease subsequent lines of chemotherapy

Breast cancer · 29 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel, nanoparticle albumin-bound and Bevacizumab Variant #01	—	R 106 729	28d	6.8 mo	—	8	R 853 833 PFS proxy	2
Trastuzumab deruxtecan monotherapy Variant #01	—	R 81 019	21d	15.5 mo	23.4 mo	23	R 1 863 446 PFS proxy	9
Pegylated liposomal doxorubicin and Bevacizumab Variant #01	—	R 51 764	28d	6.3 mo	—	7	R 362 350 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	5.3 mo	16.8 mo	6	R 274 259 PFS proxy	6
Gemcitabine and Bevacizumab Variant #01	—	R 42 428	28d	6.8 mo	—	8	R 339 425 PFS proxy	2
Paclitaxel and Bevacizumab Variant #01	—	R 40 037	28d	7.2 mo	—	8	R 320 296 PFS proxy	1
Doxorubicin and Bevacizumab Variant #01	—	R 38 931	28d	6.3 mo	—	7	R 272 514 PFS proxy	1
Docetaxel and Bevacizumab Variant #01	—	R 30 693	21d	6.8 mo	—	10	R 306 926 PFS proxy	2
Capecitabine and Bevacizumab Variant #01	—	R 29 610	21d	6.8 mo	—	10	R 296 096 PFS proxy	4
Non-pegylated liposomal doxorubicin and Bevacizumab Variant #01 Partial	—	R 28 623	21d	6.3 mo	—	10	R 286 232 PFS proxy	1
Eribulin monotherapy Variant #01	—	R 24 243	21d	4.1 mo	13.1 mo	6	R 145 460 PFS proxy	21
Vinorelbine and Bevacizumab Variant #01	—	R 19 568	14d	7.2 mo	—	16	R 313 092 PFS proxy	1
Capecitabine and Ixabepilone Variant #01	—	R 15 711	21d	5.8 mo	16.4 mo	9	R 141 400 PFS proxy	4
Pegylated liposomal doxorubicin monotherapy Variant #01	—	R 15 300	28d	3.6 mo	—	4	R 61 200 PFS proxy	2
Ixabepilone monotherapy Variant #01	—	R 14 725	21d	—	~7.5 mo	—	—	1
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	4.6 mo	11.2 mo	3	R 42 639 PFS proxy	15
Docetaxel and Gemcitabine Variant #01	—	R 4 912	21d	—	~26.9 mo	—	—	2
Cisplatin and Vinorelbine (CVb) Variant #11	—	R 4 117	42d	—	~10.0 mo	—	—	11
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	4.1 mo	—	6	R 21 978 PFS proxy	1
Capecitabine and Docetaxel (TX) Variant #01	—	R 3 056	21d	9.2 mo	14.5 mo	14	R 42 781 PFS proxy	2
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	5.4 mo	16.5 mo	6	R 13 317 PFS proxy	11
Capecitabine monotherapy Variant #17	—	R 2 219	21d	4.5 mo	15.6 mo	7	R 15 535 PFS proxy	33
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	5.1 mo	13.8 mo	8	R 10 346 PFS proxy	2
Capecitabine and Vinflunine Variant #01 Partial	—	R 814	21d	5.6 mo	—	9	R 7 324 PFS proxy	1
Vinorelbine monotherapy Variant #01	—	R 583	21d	4.0 mo	10.8 mo	6	R 3 500 PFS proxy	17
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	4.7 mo	11.4 mo	6	R 1 459 PFS proxy	5
Cyclophosphamide monotherapy N/A - secondary systemic drug	—	R 60	28d	—	9.3 mo	—	—	1
Cyclophosphamide and Methotrexate (CM) Variant #01	—	R 49	7d	—	—	—	—	—
Non-pegylated liposomal doxorubicin monotherapy Variant #01 Partial	—	—	21d	4.2 mo	—	7	—	1

29 of 29 regimens shown